What is the Origin of CJC-1299 Ipamorelin Stacks?

Both peptides were developed in the field of endocrinology and pharmacology as therapeutic agents to address growth hormone deficiency and related somatotropic axis dysfunctions. CJC-1299's long half-life, achieved through Drug Affinity Complex (DAC) technology, allows for less frequent dosing. Ipamorelin, a highly selective GHRP, minimizes the unwanted side effects, such as increased cortisol or prolactin, often seen with older secretagogues.

What is the Mechanism of CJC-1299 Ipamorelin Stacks?

CJC-1299 acts by binding to the pituitary somatotrophs' GHRH receptors, enhancing the production and release of GH. Concurrently, Ipamorelin selectively binds to the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHSR), triggering a potent GH release without significantly impacting the adrenocorticotropic or lactotropic axes. This dual action mimics the natural, pulsatile hypothalamic regulation of growth hormone secretion, supporting tissue repair, improved body composition, and enhanced metabolic function.

CJC-1299 Ipamorelin Stacks ∞ Area

CJC-1299 Ipamorelin Stacks

Meaning

CJC-1299 Ipamorelin Stacks refer to the combined clinical administration of two synthetic peptides: CJC-1299, a growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective growth hormone secretagogue (GHRP). This synergistic combination is utilized in hormonal health optimization to safely and effectively stimulate the pituitary gland’s pulsatile release of endogenous growth hormone (GH). The stacking strategy aims for a more physiological and sustained GH pulse profile compared to single-agent therapy.